Clinical Trial Update: Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085) [Phase 3]

View source ↗

Summary

This document provides a Phase 3 trial update on pegylated interferon alfa-2b in patients with hepatitis C-related cirrhosis and high liver cell proliferation, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis of the Liver
• Hepatitis C
• Hepatocellular Carcinoma

Drugs mentioned

• Pegylated Interferon Alfa-2b (pegylated interferon alfa-2b)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Hepatocellular | Phase 3 | Status: COMPLETED | Results posted: 2011-04-18